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Introduction {#sec1}
============

The identification and characterization of brite/beige (a.k.a. brown-like) adipocytes has drawn considerable attention, as these cells are thought to regulate energy production and may help combat obesity and insulin resistance ([@bib31], [@bib44]). Adult humans possess brown adipocytes that are activated by cold stimuli via the sympathetic nervous system ([@bib30], [@bib31], [@bib32]). Progenitors isolated from subcutaneous white fat from children or adults can be induced to acquire a brite phenotype ([@bib2], [@bib12], [@bib34]), characterized by enhanced oxygen consumption and expression of uncoupling protein 1 (UCP1) and cell-death inducing DNA fragmentation factor-like effector A (CIDEA).

CIDEA downregulates UCP1 activity in brown adipose tissue ([@bib53]). Originally thought to be a mitochondrial protein, CIDEA was later discovered to be a lipid droplet (LD)-associated protein ([@bib7], [@bib36], [@bib38]) not localized to mitochondria in adipocytes. Unlike in mice ([@bib53]), CIDEA expression in human adipocytes correlates with insulin sensitivity ([@bib36]) and lipid disorders in obese patients ([@bib10]). Furthermore, a CIDEA polymorphism has been associated with a clinical metabolic phenotype ([@bib8], [@bib33], [@bib50], [@bib52]). CIDEA is endogenously expressed in human but not in rodent white adipocytes. A study by Kulyte et al. provided a strong rationale to our study where they have shown that CIDEA localizes in both the cytoplasm and the nucleus and it binds to liver X receptors (LXR) to regulate their activity in human white adipocytes ([@bib23]). Also, CIDEA was found to be expressed at abnormally high levels in white adipose tissue from cachexic patients and CIDEA overexpression *in vitro* inhibited glucose oxidation while stimulating fatty acid oxidation (FAO) ([@bib24]). Transgenic mice expressing human-CIDEA specifically in adipose tissue show an improved metabolic profile through expansion of adipose tissue ([@bib1]), suggesting that human CIDEA might be functionally different than the mouse CIDEA. Considered a brown adipocyte marker in mice, CIDEA expression increases with britening of mouse white adipocytes ([@bib3], [@bib17], [@bib18], [@bib29], [@bib37], [@bib41], [@bib40], [@bib45], [@bib46]). Beyond its associations with thermoregulation ([@bib3], [@bib17], [@bib29], [@bib37], [@bib41], [@bib45]), lipid droplet dynamics, and lipid metabolism ([@bib4], [@bib36], [@bib51]), little is known about the molecular role of CIDEA in britening and thermogenesis of human adipocytes.

To delineate the association of CIDEA with thermogenesis in humans, we established a positive correlation of CIDEA and UCP1 expression in britened human adipose tissue. We then used human primary white adipose tissue-derived stromal vascular cells (hADSCs) as a model system and developed dual RNA-based CRISPR-Cas9 system to knock out CIDEA in primary human cells. We also developed a modified RNA methodology for dose-dependent expression of CIDEA in human adipocytes. Brite adipocytes exhibited elevated UCP1 expression and increased mitochondrial biogenesis along with brite/beige markers. Our studies reveal that during britening CIDEA expression increases and it translocates to the nucleus via a nuclear bipartite signal. In the nucleus, CIDEA induces a brite phenotype in human adipocytes by transcriptional regulation of UCP1 via directly interacting with Liver X Receptor alpha, LXRα, and weakening its binding to UCP1 enhancer. Our studies also identified that CIDEA strengthened PPARγ binding to UCP1 enhancer. Overall, our study identifies a molecular mechanism of CIDEA-mediated regulation of britening and maintenance of brite phenotype in primary human adipocytes.

Results {#sec2}
=======

CIDEA Expression in Human Brite Adipose Tissue Correlates with UCP1 Expression {#sec2.1}
------------------------------------------------------------------------------

Treatment of subcutaneous white adipose tissue explants from five obese human subjects with 1 μM rosiglitazone (Rosi) for 7 days induced CIDEA and UCP1 expression reliably ([Figure S1](#mmc1){ref-type="supplementary-material"}A). An average 2.5-fold increase in CIDEA expression correlated with an \~55-fold increase in UCP1 expression, which was negligible without treatment. This britening process was independent of demographics and body mass index. These preliminary studies complimented the role of CIDEA in healthy metabolic phenotype in humans ([@bib8], [@bib10], [@bib16], [@bib33], [@bib36], [@bib50], [@bib52]).

Modified CRISPR-Cas9nD10A Methodology to Knock Out CIDEA in Cultured Human Primary Adipocytes {#sec2.2}
---------------------------------------------------------------------------------------------

To study the loss of function of CIDEA in human primary cells, we established a modified efficient genome engineering method for genetic manipulation in adipocytes differentiated from hADSC. We modified the existing CRISPR/Cas9 system to knock out CIDEA in multipotent human adipose-derived stromal progenitor cells (hADSCs) from freshly isolated human subcutaneous adipose tissue. To achieve an efficient CIDEA knockout (KO), we designed multiple single guide RNA (sgRNA) in combination of Cas9 or its mutated form to target the CIDEA gene loci ([Figure 1](#fig1){ref-type="fig"}A; also see [Figures S1](#mmc1){ref-type="supplementary-material"}, [S2](#mmc1){ref-type="supplementary-material"}, and [S3](#mmc1){ref-type="supplementary-material"}A--S3C and [Supplemental Information](#mmc1){ref-type="supplementary-material"}). With our modified CRISPR-Cas9nD10A nickase methodology, we were able to knock out CIDEA in human adipocytes ([Figure 1](#fig1){ref-type="fig"}B).Figure 1CIDEA KO Inhibits Britening of Human White Adipocytes(A) CRISPR-Cas9 construction. Hybrid Cas9 construct (Cas9^D10A^-2A-P) and modified human Cas9 mRNA synthesis workflow.(B) Western blot showing CRISPR-Cas9D10A nickase-mediated abolishment of CIDEA in four biallelic clones of mature adipocytes.(C) CIDEA protein expression profile after dose-dependent mcom CIDEA mRNA single transfection (24 h) into human white adipocytes. Mouse brown adipocyte (mBA) lysate was blotted as a positive control.(D) Time course expression profile of mcom CIDEA mRNA after single transfection into Hek293T cells. Modified codon-optimized *CIDEA* mRNA (mcom CIDEA-mRNA; also called CIDEA mod mRNA) produced eloquent dose- and time-dependent control of CIDEA expression (C and D).(E and F) Expression of thermogenic genes (E) and UCP1 (F) in Rosi-treated WT (CIDEA^+/+^) and KO (CIDEA^−/−^) T-brites derived from hADSCs. CIDEA^−/−^ cells were derived from WT hADSCs by CRISPR-CAS9-mediated KO. Data are expressed as fold changes over dimethyl sulfoxide (DMSO; vehicle)-treated adipocytes, and each data point represents pooled cell fractions from three individual donors. Data are mean ± SEM (n = 3). \*\*\*p \< 0.001, and \*\*p \< .01, two-way ANOVA followed by Bonferroni post tests.(G and H) Protein expression of thermogenic (G) and brite genes (H) in CIDEA^+/+^ and CIDEA^−/−^ T-brites treated with Rosi. After 7 days of Rosi, CIDEA^−/−^ adipocytes were transfected with GFP control mRNA or mcom-CIDEA mRNA (red box) to re-express CIDEA for 3 days. Each lane in the red box represents an individual CIDEA^−/−^ clone.

We next developed a modified-mRNA methodology to perform gain-of-function studies ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Modified codon-optimized CIDEA mRNA (mcom CIDEA-mRNA; also called CIDEA mod mRNA) produced eloquent dose- and time-dependent control of CIDEA expression within physiological limits ([Figures 1](#fig1){ref-type="fig"}C and 1D; also see [Methods](#sec4){ref-type="sec"} and [Figures S3](#mmc1){ref-type="supplementary-material"}E--S3G). In all our further studies, 1--2 μg mcom CIDEA-mRNA was used.

Thiazolidinedione-Induced Human Adipocyte Britening {#sec2.3}
---------------------------------------------------

Human brite adipocytes, termed T-brites, were obtained by treating mature white adipocytes, that had been differentiated from hADSCs ([@bib26], [@bib25]), with 1 μg/mL Rosi for 7 days. Relative to untreated control cells, T-brites had increased mRNA expression of PPARγ target genes (*ADIPOQ*, *FABP3*, *FABP4*, and *RXRA*) and brite/beige marker genes (*PGC1α/β*, *PRDM16*, *CEBPβ*, *CIDEA*, and *ELOVL3*), without expression changes in lipogenic genes (*FASN* and *SCD1*) ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). Notably, T-brites exhibited an 85-fold increase in *UCP1* mRNA expression ([Figure S4](#mmc1){ref-type="supplementary-material"}C) together with increased mRNA expression of other brite marker genes (*CITED*, *TBX1*, *MTUS1*, and *KCNK3*) ([Figure S4](#mmc1){ref-type="supplementary-material"}D). We did not detect changes in the transcription of brown or white marker genes ([Figures S4](#mmc1){ref-type="supplementary-material"}E and S4F, respectively). Induction of *PGC1α* and *PGC1β* transcription in T-brites was accompanied by increased transcription of mitochondrial complex I--V components ([Figure S4](#mmc1){ref-type="supplementary-material"}G).

T-brites showed upregulated *PLIN1* and *ATGL* transcription but downregulated transcription of ATGL\'s inhibitor G0S2 ([Figure S4](#mmc1){ref-type="supplementary-material"}H). Meanwhile, mRNA levels of *FSP27*, which negatively regulates lipolysis ([@bib14], [@bib42]), were unchanged in T-brites, perhaps due to positive regulation by Rosi ([@bib35], [@bib36]). T-brites exhibited upregulated mRNA expression of acyl coenzyme A dehydrogenase genes (VLCAD, *LCAD*, *MCAD*) and other FAO-associated genes (*PPAR*α, *CPT1*, *CPT2*) ([Figure S4](#mmc1){ref-type="supplementary-material"}I). The mRNA abundances of TCA cycle enzyme genes (MDH2 and IDH3a) were also increased in T-brites ([Figure S4](#mmc1){ref-type="supplementary-material"}J). T-brites were found to have elevated mitochondrial DNA contents (data not shown), consistent with increased mitochondrial biogenesis and activity, accompanied by increased FAO and TCA cycle entry characteristic of uncoupling events leading to thermogenesis.

Absence of CIDEA Inhibits Britening and Uncoupling in Human Adipocytes {#sec2.4}
----------------------------------------------------------------------

As predicted, CIDEA expression was plentiful in CIDEA^+/+^ T-brites produced by Rosi induction ([Figure 1](#fig1){ref-type="fig"}E). By comparison, CIDEA^−/−^ T-brites produced by CRISPR-Cas9 KO in hADSCs had reduced *PGC1α*, *DIO2*, *Elovl3*, and *UCP1* mRNA expression ([Figures 1](#fig1){ref-type="fig"}E and 1F), with no significant changes in *PGC1β*, *PRDM16*, and *CEBPβ* mRNA expression ([Figure 1](#fig1){ref-type="fig"}E). Other brite genes were reduced in CIDEA^−/−^ T-brites ([Figure S5](#mmc1){ref-type="supplementary-material"}A). BAT markers ([Figure S5](#mmc1){ref-type="supplementary-material"}B) and lipogenic genes (*FASN* and *SCD1*; data not shown) were unaffected by CIDEA KO. Expression of the FAO regulatory genes *CPT1* and *CPT2* was decreased, whereas *PPARα*, *VLCAD*, *LCAD*, and *MCAD* mRNA levels were unaltered ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Britening-induced increases in mitochondrial DNA copy number were unaffected by CIDEA KO ([Figure S5](#mmc1){ref-type="supplementary-material"}D). Select electron transport chain genes were downregulated in CIDEA^−/−^ T-brites ([Figure S5](#mmc1){ref-type="supplementary-material"}E), whereas adipogenic gene expression did not differ between CIDEA^+/+^ and CIDEA^−/−^ T-brites (data not shown). CIDEA KO reduced protein expression of PGC1α (PPARγ coactivator 1 alpha), UCP1, CPT (carnitine palmitoyltransferase) 2, CITED (Cbp/P300 interacting transactivator with Glu/Asp-rich carboxy-terminal domain), MTUS (microtubule-associated scaffold protein)1, TBX1 (T-box 1), and KCNK3 (potassium two-pore domain channel subfamily K member 3) but not PPARγ, PRDM16 (PR domain containing 16), CEBPβ (CCAAT/enhancer-binding protein beta), and TMEM (TransMEMbrane protein); these reductions were reversed by CIDEA re-expression ([Figures 1](#fig1){ref-type="fig"}G and 1H, red box). These results suggest that CIDEA plays an important role in adipocyte britening via regulation of thermogenic genes.

CIDEA KO Diminishes Increased OCR in T-Brites {#sec2.5}
---------------------------------------------

The basal oxygen consumption rate (OCR) was higher in T-brites than in white adipocytes ([Figure 2](#fig2){ref-type="fig"}A). Relative to non-KO controls, CIDEA^−/−^ T-brites had reduced mitochondrial respiration, proton leakage, and maximal respiratory capacity ([Figure 2](#fig2){ref-type="fig"}B) but unchanged coupling efficiency and thus unchanged mitochondrial energy production ([Figure S6](#mmc1){ref-type="supplementary-material"}A). These data revealed that irrespective of britening or CIDEA\'s absence, the efficiency of mitochondrial energy production, above the oligomycin-mediated ATP-block, was same under basal conditions. The cell respiratory ratio (cRCR), a respiratory capacity index, was higher in T-brites than in white adipocytes ([Figure S6](#mmc1){ref-type="supplementary-material"}B). CIDEA KO did not change cRCR, arguably owing to reduced substrate oxidation and proton leakage because cRCR is sensitive to these factors but insensitive to ATP turnover.Figure 2CIDEA KO Inhibits UCP1-dependent OCR in Human Adipocytes Induced for Britening(A) Seahorse bioanalyzer respirometry of differentiated WT and CIDEA^−/−^ white adipocyte and T-brites show basal respiration, proton leak respiration (after 2 μm oligomycin treatment), maximal substrate oxidation (12 μm FCCP), and non-mitochondrial respiration (5 μm/5 μm antimycin A/rotenone). All data points are an average of 8--10 wells.(B) Quantification of basal respiration, ATP turnover, proton leak, and maximum respiratory capacity of the samples in panel (A).(C) Bioenergetics of ISO-induced OCR of WT and CIDEA^−/−^ T-brites pretreated with vehicle (DMSO) or FFA-induced leak respiration blocker (2 h, 20 μm orlistat; 12 h, 6 μg/mL CSA; 1% BSA).(D) Lipolysis suppression, PTP blockade, or FFA scavenging inhibited ISO-induced leak respiration in CIDEA^−/−^ T-brites.(E) Time course OCR of WT and CIDEA^−/−^ white and brite/beige adipocytes treated with 50 μM arotinoid acid (TTNPB) or DMSO or after basal and oligomycin-dependent respiration. FCCP and antimycin A/rotenone were added subsequently.(F) TTNPB increased uncoupled/leak respiration in brite/beige cells in UCP1-dependent manner.Data in (B), (D), and (F) are mean ± SEM (n = 3). \*\*\*p \< 0.001 and \*\*p \< .01, two-way ANOVA followed by Bonferroni post tests.

CIDEA-Mediated Increase in OCR Is UCP1 Dependent {#sec2.6}
------------------------------------------------

CIDEA inhibition has been shown to increase stimulated lipolysis, thus increasing free fatty acids (FFAs) ([@bib36]). We found that basal lipolysis was increased in CIDEA^−/−^ adipocytes ([Figure S2](#mmc1){ref-type="supplementary-material"}E). Excessive production of intracellular FFAs during lipolysis can mask UCP1-mediated leak respiration through non-specific protonophoric FFA actions and mitochondrial permeability transition pore (PTP) opening ([@bib28]). Therefore, we compared T-brite OCRs in wild-type (WT) CIDEA^+/+^ versus KO CIDEA^−/−^ T-brites stimulated with isoproterenol (ISO), to differentiate CIDEA\'s involvement in UCP1 activity versus PTP-mediated leak respiration. Injection of T-brites at 30 min time point with the β-adrenoreceptor agonist ISO (to increase endogenous FFAs) increased OCR, with or without CIDEA ([Figures 2](#fig2){ref-type="fig"}C and 2D). Maximization of oxidative capacity with the protonophore FCCP \[carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone\] during ISO-induced OCR was lower in CIDEA^−/−^ than in CIDEA^+/+^ T-brites, evidencing a contribution of CIDEA to mitochondrial reserve capacity and uncoupling ([Figure 2](#fig2){ref-type="fig"}C). ISO-induced ATP-linked respiration showed no significant difference in CIDEA^−/−^ and CIDEA^+/+^ T-brites ([Figures 2](#fig2){ref-type="fig"}C and 2D), indicating that proton leak was masked in CIDEA^−/−^ cells. Therefore, to assess UCP1\'s contribution to uncoupled T-brite respiration, we suppressed excess FFA-mediated proton leakage via PTPs with a pretreatment with the lipase inhibitor orlistat, the PTP blocker cyclosporin A (CSA) or the FFA sink BSA (BSA, 1%). The reducing effects of orlistat and 1% BSA on PTP-dependent (UCP1-independent) proton-leak respiration were more pronounced in CIDEA^−/−^ than in CIDEA^+/+^ T-brites, implicating UCP1 dependence in CIDEA-mediated increases in OCR; the CSA effect did not differ significantly between WT and KO cells ([Figures 2](#fig2){ref-type="fig"}C and 2D). Taken together, these results showed that CIDEA KO reduced UCP1-dependent uncoupled respiration.

To further assess the direct contribution of UCP1 to OCR, we administered UCP1 activator, TTNPB (the retinoid analog), after inhibiting coupled oxygen consumption with oligomycin. Because TTNPB increases proton conductance through the inner mitochondrial membrane, we hypothesized that the number of UCP1 molecules present in the inner mitochondrial membrane might correlate with TTNPB-mediated increased respiration. After dose optimization for OCR augmentation without cytotoxicity (data not shown), 50 μM TTNPB was found to have a more robust OCR augmentation effect on oligomycin-inhibited CIDEA^+/+^ T-brites than on CIDEA^−/−^ T-brites ([Figures 2](#fig2){ref-type="fig"}E and 2F); white adipocytes did not respond to TTNPB. CIDEA\'s role in UCP1-mediated OCR was further confirmed when CIDEA re-expression in CIDEA^−/−^ cells, using CIDEA mcomRNA, restored the TTNPB-induced increase in respiration to nearly the level of control T-brites ([Figures S6](#mmc1){ref-type="supplementary-material"}C and S6D). TTNPB did not alter FCCP efficacy, suggesting different modes of action for the two agents ([Figure 6](#fig6){ref-type="fig"}C). Finally, elevated oxidative phosphorylation subunit levels in T-brites, compared with white adipocytes, were decreased by CIDEA KO and recovered with CIDEA re-expression ([Figure S6](#mmc1){ref-type="supplementary-material"}E).

CIDEA Is Critical for Adipocyte Britening by Various Inducers {#sec2.7}
-------------------------------------------------------------

To confirm that the role of CIDEA in britening was not specific to Rosi, britening of mature human white adipocytes was induced with a 7-day exposure to 1 nM CL316,243 (a β3 agonist), 100 nM fibroblast growth factor 21 (FGF21), or 100 nM atrial natriuretic peptide (ANP; dosage optimization data not shown) in the presence or absence of CIDEA and confirmed by the characteristics of high mitochondrial content, UCP1 expression, and thermogenic capacity ([@bib5], [@bib13], [@bib15]). In all cases, levels of transcripts encoding UCP1, PGC1α, CIDEA, PRDM16, and CPT2 transcript levels were robustly increased relative to levels in white adipocytes ([Figure S7](#mmc1){ref-type="supplementary-material"}A). In addition to reducing UCP1 transcription in response to these inducers, KO of CIDEA was associated with lesser induction of several thermogenic and brite marker mRNAs (precise effects varied among inducers, see [Figure S7](#mmc1){ref-type="supplementary-material"}A). Consistent with these mRNA expression data, CIDEA^−/−^ T-brites had lower UCP1, PGC1α, MTUS1, and CITED1 protein expression than CIDEA^+/+^ T-brites ([Figure S7](#mmc1){ref-type="supplementary-material"}B). In consonance with our previous finding of CIDEA\'s role in LD morphology ([@bib7], [@bib36]), relative to CIDEA^+/+^ T-brites, CIDEA^−/−^ T-brites had reduced LD sizes after being treated with britening inducers ([Figure S8](#mmc1){ref-type="supplementary-material"}A).

CIDEA KO rendered britening activators less effective at raising UCP1-dependent OCR (in the presence of a PTP inhibitor) ([Figure S8](#mmc1){ref-type="supplementary-material"}B). ISO-induced proton leakage (respiratory uncoupling) was also reduced in CIDEA^−/−^ T-brites in the presence of the PTP inhibitor ([Figure S8](#mmc1){ref-type="supplementary-material"}C). Similar results were obtained in the presence of 1% BSA, which was used to mask non-specific FFA effects ([Figures S8](#mmc1){ref-type="supplementary-material"}D and S8E). These results suggested that CIDEA acts as a regulator of human adipocyte britening, independent of the induction pathway triggered.

Transcriptome Analysis in Britened Human White Adipocytes in the Presence and Absence of CIDEA {#sec2.8}
----------------------------------------------------------------------------------------------

To perform transcriptome analysis, we transdifferentiated white adipocytes into brite adipocytes with a cocktail containing Rosi, FGF21, ANP, and β3 agonist. The idea was to examine the global effect of britening and thermogenic response in CIDEA^−/−^ and CIDEA^+/+^ T-brites. We identified unique gene signature of brite or thermogenic genes affected by the complete absence of CIDEA ([Figure 3](#fig3){ref-type="fig"}A). Differential gene expression analysis with applied filters (ANOVA p \< 0.05 and linear fold change \< -2 or .2) revealed upregulation of 1,757 genes and downregulation of 1,982 genes in the CIDEA^−/−^ T-brite adipocytes. Furthermore, expression clustering of selected highly downregulated ([Figure 3](#fig3){ref-type="fig"}B) and highly upregulated ([Figure 3](#fig3){ref-type="fig"}C) genes in the CIDEA^−/−^ T-brites indicate CIDEA\'s control over thermogenic and metabolic functions. The differentially expressed genes were categorized by gene ontology analysis (GO) followed by DAVID analysis ([Figure 3](#fig3){ref-type="fig"}D). The GO analysis revealed that genes involved in overall thermogenic functions including adaptive thermogenesis (GO:1990845), fatty acid oxidation (GO:0019395), mitochondrial transport (GO:0006839), electron transport chain (GO:0022900), cellular respiration (GO:0045333), ATP metabolic process(GO:0046034), coenzyme metabolism (GO:0006732), response to lipid (GO:0033993), and response to insulin stimulation (GO:0032869) were also downregulated in the CIDEA^−/−^ T-brite group. In addition to the downregulation of well-established gene network related to thermogenic function, CIDEA^−/−^ T-brites showed suppression of Creatine kinase (CKMT1) expression. Recently, CkMT1-driven creatine cycle has been shown to be involved in UCP1-independent brite adipocyte thermogenic program ([@bib22]). This analysis indicated a possible role of CIDEA in thermogenesis in the brite adipocytes.Figure 3A Whole-Genome Transcriptome Microarray Analysis of T-brite Adipocytes ± CIDEA(A) Volcano plot from hierarchical clustering of differentially expressed genes in T-brite human adipocytes ± CIDEA (n = 3 in each group). Plot demonstrates a decrease in defined thermogenic (UCP1, EBF2, CKMT1A, CKMT1B) and transmembrane markers in T-brite adipocytes in the absence of CIDEA. UCP1 was most upregulated upon britening of human white adipocytes in the presence of CIDEA.(B) Heatmap of select highly downregulated genes in T-brite adipocytes in the absence of CIDEA (Fold enrichment ≥3.8, p \< 0.05).(C) Heatmap of select highly upregulated genes in T-brite adipocytes in the absence of CIDEA (Fold enrichment ≥−4.5, p \< 0.05).(D) Pathway analysis of differentially regulated genes. Analysis of select GO terms enriched in the differentially regulated genes, downregulated in CIDEA-KO T-brites compared with the wild-type T-brites, with fold changes ≥3.85 (p \< 0.05).The number on each pie slice indicates the number of genes in the respective GO terms.(E) Venn Diagram analysis of individual GAD disease gene sets (colored circles) from the corresponding downregulated (Fold enrichment ≥3.8, p \< 0.05) genes in CIDEA-KO T-brites.All Venn Diagrams were produced with Venny <http://bioinfogp.cnb.csic.es/tools/venny/index.html>. The numbers on the Venn diagram indicate the number of genes shared or unshared between the indicated disease.

Next, we categorized the highly downregulated gene sets in CIDEA^−/−^ T-brite adipocytes to the human genetic association database (GAD) to identify the significance of CIDEA in beige adipocyte function with the related metabolic disease. GAD primarily links common complex human disease rather than rare Mendelian inheritance in man (OMIM). GAD analysis indicated common metabolic disease linked to highly downregulated genes in CIDEA^−/−^ T-brite adipocytes. Venn diagram comparison among related GAD disease showed modest gene sharing as shown in [Figure 3](#fig3){ref-type="fig"}E. This disease-related sharing at the gene level suggests a common regulatory mechanism governing britening/thermogenesis, obesity, insulin resistance, type II diabetes, and metabolic syndrome. Interestingly, CIDEA polymorphism is well connected with metabolic syndrome in humans ([@bib8], [@bib33], [@bib50], [@bib52]). Indeed, a recent study showed that human-CIDEA specifically expressed in mouse adipose tissue improves whole-body metabolic phenotype ([@bib1]).

CIDEA Nuclear Localization Depends on a Bipartite Nuclear Localization Signal {#sec2.9}
-----------------------------------------------------------------------------

CIDEA expression started increasing after 12 h upon britening induction and plateaued at 144 h ([Figure S9](#mmc1){ref-type="supplementary-material"}A). Subcellular fractionation revealed nuclear localization of CIDEA beginning 24 h and peaking 48 h after britening induction ([Figure 4](#fig4){ref-type="fig"}A). Perilipin (PLIN1; negative control) remained in the lipid fraction throughout the process. Interestingly, CIDEA enrichment in the nucleus increased 5 h after ISO treatment ([Figure 4](#fig4){ref-type="fig"}B). This localization was blunted by a simultaneous cycloheximide treatment ([Figure S9](#mmc1){ref-type="supplementary-material"}B). During ISO treatment, FFA/BSA blocked nuclear enrichment but enhanced CIDEA concentrations in the lipid fraction ([Figure 4](#fig4){ref-type="fig"}C). These results suggest that shuttling of CIDEA from LDs to the nucleus depends on its concentration and lipid availability. A competitive assay in which LD-associated CIDEA was saturated with 3×HA-CIDEA-mcomRNA before adding 6×His-CIDEA mcomRNA showed that, at a fixed saturable concentration of 3×HA-CIDEA, 6×His-CIDEA was enriched dose dependently in CIDEA^−/−^ T-brite nuclei ([Figure 4](#fig4){ref-type="fig"}D). In fact, the localization of 6×His-CIDEA suggested retrograde nucleus-to-LD shuttling of CIDEA. Bipartite nuclear localization signal (NLS) mapping demonstrated that the 21--49 amino acid (aa) region of human CIDEA, which contains two basic aa clusters separated by a 21-aa spacer, has a high nuclear score of 4.0 ([Figure 4](#fig4){ref-type="fig"}E). Similar sequence in mouse and rat showed lower nuclear score. This indicates a high probability of nuclear localization of human CIDEA. Deletion of the NLS (1--219ΔNLS) or substitution of a key lysine (K23A) or arginine (R44A) disrupted CIDEA nuclear localization ([Figure 4](#fig4){ref-type="fig"}F), whereas mutation of unrelated arginines (R13A, R127A) did not (data not shown), demonstrating NLS specificity for nuclear localization. These results confirm the importance of bipartite NLS for nuclear entry of human CIDEA.Figure 4Nuclear Shuttling of CIDEA(A) Time courses of CIDEA protein expression in human white adipocytes after addition of 1 μm Rosi.(B) Time-dependent LD versus nuclear enrichment of CIDEA after ISO-induction of T-brites.(C) Compartmentalization of CIDEA in LDs and nuclei after albumin-bound FFA-mix challenge 6 h after ISO induction. FFA-mix (FFA/BSA) challenge inhibited CIDEA nuclear accumulation with concomitant LD enrichment.(D) Competitive import assay showing dose-dependent nuclear enrichment of 6×His-CIDEA at fixed saturable concentration of 3×HA-CIDEA. The CIDEA^−/−^ T-brites were transfected initially with 3×HA-CIDEA (4 μg in each of 6 wells) and then 6 h later with 6×His-CIDEA. The cells were harvested 12 h after the last transfection.(E) Top: hCIDEA protein sequence with putative NLS at aa 21--49 (red box). Critical lysine (K23) and arginine (R44) residues are marked green; irrelevant arginines are marked red. Bottom: alignment and comparison of human bipartite NLS with mammalian analogs. Localization prediction scores were obtained from cNLS Mapper.(F) Confocal images showing nuclear and LD localization of HA-tagged FL CIDEA and mutant CIDEA (K23A/R44A substitution or NLS deletion \[ΔNLS\]) in T-brites. Cells were labeled with anti-HA primary antibody followed by AF-488 secondary antibody.

We tested whether CIDEA translocation to the nucleus depends on passive diffusion through nuclear pore complexes or α/β importin-Ran-GTPase-mediated active transport. The α/β importin inhibitor ivermectin did not affect CIDEA nuclear import, indicating that it does not require active transport via α/β importin-Ran-GTPase, but blocked the import of HA-t-Ag containing a monopartite NLS recognized by α/β importin ([Figure S9](#mmc1){ref-type="supplementary-material"}C). Apyrase, a nucleotide hydrolase, reduced nuclear import of CIDEA ([Figure S9](#mmc1){ref-type="supplementary-material"}C). These data suggest that CIDEA nuclear entry is at least partially ATP dependent, perhaps facilitated by NLS-binding carrier molecules or may be via protein piggybacking.

CIDEA Is a Transcriptional Activator of UCP1 during Britening {#sec2.10}
-------------------------------------------------------------

We next identified the region of UCP1 promoter/enhancer associated with CIDEA-mediated regulation of UCP1 transcription. Experiments with various luciferase-*UCP1* constructs ([Figure 5](#fig5){ref-type="fig"}A) showed that the 150-bp proximal minimal region of the UCP1 distal enhancer was crucial for CIDEA-mediated upregulation of UCP1 distal enhancer activity ([Figure 5](#fig5){ref-type="fig"}B). Interestingly, this region contains previously characterized DR4 and DR1 sequences; LXR binds DR4 to downregulate UCP1 expression, whereas PPARγ binds DR1 to upregulate UCP1 expression ([@bib20], [@bib47]). Therefore, to examine whether CIDEA-mediated UCP1 regulation depends on the DR1 or DR4 sequences, we generated DR1 and DR4 loss of function mutation on 150 bp proximal enhancer sequence ([Figure 5](#fig5){ref-type="fig"}C; top three rows). Addition of CIDEA mcomRNA activated the intact minimal distal enhancer ([Figure 5](#fig5){ref-type="fig"}D, DR4-DR1). Deletion of DR1 abrogated enhancer activity completely, whereas deletion of DR4 increased enhancer activity, independent of exogenous CIDEA ([Figure 5](#fig5){ref-type="fig"}D), suggesting that DR4-LXR binding might mediate CIDEA upregulation of UCP1. To further delineate the association of CIDEA with the DR4 element, we generated gain-of-function mutants of DR1 and DR4 elements. We speculated that increased number of DR1 or DR4 would enhance the binding of LXRα and PPARγ, respectively. Therefore, we generated two separate 150-bp LUC constructs, one containing three DR4 (3xDR4) with one DR1 element (1xDR1) and other containing three DR1 (3xDR1) with one DR4 element ([Figure 5](#fig5){ref-type="fig"}C; botom two rows).Transfection of 3xDR1:1xDR4 construct resulted in a profound increase in enhancer activity independent of CIDEA, whereas 3xDR4:1xDR1 had no effect on basal enhancer activity, but it robustly responded to exogenous CIDEA ([Figure 5](#fig5){ref-type="fig"}D). These results suggest that CIDEA-mediated UCP1 upregulation occurs via DR4, a sequence known to bind LXR to negatively regulate UCP1 expression ([@bib47]).Figure 5CIDEA Regulates *UCP1* Transcription during Human Adipocyte Britening(A) hUCP1-Luc-pGL-3 constructs, including WT (−6,000 to +1) and seven deletion mutant constructs.(B) Relative luciferase (rLUC) activity of each construct in response to exogenous CIDEA (12 h after transfection of mcom-CIDEA). Constructs were transfected into T-brites 24 h before transfection of mcom-CIDEA (0.750 pg/cell) or control (glyceraldehyde 3-phosphate dehydrogenase \[GAPDH\]; 0.750 pg/cell) mRNA.(C) Synthetic dUER~150bp~ constructs containing DR1 (PPARγ-binding site) or DR4 (LXR-binding site) were cloned into a pGL-3 LUC vector for functional analysis.(D) CIDEA (0.750 pg/cell) induction of the *UCP1* promotor (150-bp WT, DR1--DR4); the ΔDR1 and ΔDR4 mutations disrupted CIDEA induction in opposite manner.(E) Exogenous LXRα or LXRα+RXRα mRNA but not LXRβ or LXRβ+RXRα mRNA (all mRNAs: 0.750 pg/cell) suppressed expression of synthetic dUER~150bp~ luciferase construct containing WT DR4 (DR4-DR1); this suppression was abolished with mutant DR4 (ΔDR4-DR1).(F) Effect of exogenous mcom-CIDEA mRNA on rLUC of dUER~150bp~ construct. T-brites were transfected with WT or mutant DR4 luciferase constructs 24 h before transfection with *CIDEA* mRNA (0.750 pg/cell).(G) *In vitro* biotin-streptavidin DNA pull-down assay for protein-DNA interaction strength assessment of *in vitro* translated human recombinant (r)CIDEA, rLXRα, and rPPARγ to dUER~150bp~ or a DR1 or DR4 oligonucleotide. LXRα and PPARγ heterodimeric partner RXRα and their respective ligands were added to facilitate DNA binding. Unlike rLXR and rPPAR, no rCIDEA was pulled down with an equivalent amount of biotinylated DNA as detected by western blotting.(H) Protein-DNA binding analysis of rCIDEA with dUER~150bp~ and DR4 in the presence of rLXRα and RXRα (blue box). Interaction strength of rLXRα with dUER~150bp~ was reduced with increasing rCIDEA concentration (red box). No CIDEA was recovered by streptavidin pull down followed by western blotting in the absence of a cross-linker. HCHO + EGS cross-linking, but not HCHO-only cross-linking, pulled down CIDEA, revealing a distant CIDEA-LXRα interaction.(I) Progressive addition of BSA (negative control) did not affect LXRα-DR4 interaction.In (B), (D), (E), and (F), data are mean rLUC (relative to pGL-3 basic vector) ± SEM (n = 3). \*\*\*p \< 0.001, \*\*p \< .01, and \*p \< .05; two-way ANOVA followed by Bonferroni post tests.

We next measured UCP1 enhancer activity in the presence of LXRα or LXRβ alone or with their obligatory heterodimeric partner RXRα. Exogenous LXRα, but not LXRβ, suppressed *UCP1* enhancer activity, consistent with a previous study demonstrating similar selectivity in mice ([@bib47]), and this effect was absent with the deleted-DR4 construct ([Figure 5](#fig5){ref-type="fig"}E). Importantly, CIDEA along with LXRα alone or with its obligatory heterodimeric partner RXRα countered this LXRα-mediated suppression of UCP1 enhancer activity ([Figure 5](#fig5){ref-type="fig"}F). LXRα agonism with T0901317 reduced *UCP1* mRNA expression in CIDEA^−/−^ T-brites with or without ISO but only with ISO in CIDEA^+/+^ T brites ([Figure S10](#mmc1){ref-type="supplementary-material"}A). Similar results were obtained with GW3965, another LXR agonist (data not shown). We attempted to study the effect of CIDEA by knocking out LXRα by CRISPR, but the LXRα knockout cells did not grow well, showing that LXRα might also have a role in cellular growth and/or development. Therefore, we used small interfering RNA (siRNA) to knock down LXRs. siRNA-mediated knockdown of LXRα, but not LXRβ, increased UCP1 protein expression in T-brites, indicating that LXRβ does not regulate UCP1 expression and also may not compensate for LXRα ([Figure S10](#mmc1){ref-type="supplementary-material"}B). Moreover, uncoupled respiration was increased in LXRα-, but not LXRβ-, depleted T-brites, independent of CIDEA ([Figure S10](#mmc1){ref-type="supplementary-material"}C). Overall, our observations indicate that CIDEA affects *UCP1* transcription via LXRα.

CIDEA-LXR Dynamics Is Key to *UCP1* Transcriptional Regulation {#sec2.11}
--------------------------------------------------------------

To test whether CIDEA has any direct interaction with UCP1 enhancer region, we performed *in vitro* biotinylated-DNA pull-down assays coupled with immunoblots. As shown in [Figure 5](#fig5){ref-type="fig"}G, CIDEA did not bind the 150-bp UCP1 distal enhancer region (dUER~150bp~), nor the DR1 or DR4 oligonucleotides, even in the presence of the LXRα heterodimeric partner RXRα ([Figure 5](#fig5){ref-type="fig"}G; top blots). Subsequent assays were performed in the presence of RXRα and the LXRα agonist, T0901317. LXRα ([Figure 5](#fig5){ref-type="fig"}G; middle blots) and PPARγ ([Figure 5](#fig5){ref-type="fig"}G; lower blots) bound their cognate sequences as efficiently as they bound dUER~150bp~.

Streptavidin pull-down assays of biotinylated dUER~150bp~, DR4, or DR1 sequences did not recover any CIDEA in the presence of LXRα or PPARγ ([Figure 5](#fig5){ref-type="fig"}H, blue box), suggesting that CIDEA may not bind the enhancer via LXRα or PPARγ. Unlike cross-linking with Formaldehyde (Short cross-linking spacer arm, \~2 A°), cross-linking with Formaldehyde-EGS (long spacer arm, \~16.1 A°) revealed a transient interaction of CIDEA with DR4 ([Figure 5](#fig5){ref-type="fig"}H) but not with DR1 ([Figure S10](#mmc1){ref-type="supplementary-material"}D, blue box). As a positive control, biotinylated DR4 and DR1 pulled down LXRα and PPARγ, respectively ([Figures 5](#fig5){ref-type="fig"}H and [S10](#mmc1){ref-type="supplementary-material"}D). Interestingly, LXRα binding with its cognate DR4 element in dUER~150bp~ was weakened with increasing CIDEA ([Figure 5](#fig5){ref-type="fig"}H, red box), but not BSA ([Figure 5](#fig5){ref-type="fig"}I), concentrations, demonstrating the CIDEA binding specificity for LXRα. CIDEA had no effect on PPARγ binding to DR1 ([Figure S10](#mmc1){ref-type="supplementary-material"}D; red square). PPARγ and its ligand rosiglitazone did not affect CIDEA-mediated inhibition of LXRα-DR4 binding ([Figure S10](#mmc1){ref-type="supplementary-material"}E). Overall, the above-mentioned results show that CIDEA interacts with LXRα, which weakens LXRα binding to DR4.

CIDEA Directly Binds to LXRα and Weakens Its Binding to UCP1 Enhancer {#sec2.12}
---------------------------------------------------------------------

To further test that CIDEA weakens LXRα binding to DR4, we produced a single-nucleotide (T-G) mutation one nucleotide before the DR4 core sequence, resulting in an AatII restriction site outside of DR4 ([Figure 6](#fig6){ref-type="fig"}A). The idea was that LXRα binding to DR4 would inhibit the cleavage with AatII restriction enzyme. As expected, in the absence of LXRα, there was a cleavage with AatII restriction enzyme, which was otherwise blocked by LXRα binding ([Figure 6](#fig6){ref-type="fig"}B). Interestingly, when this construct was incubated with LXRα, AatII cleavage of DR4 increased with increasing concentrations of CIDEA ([Figure 6](#fig6){ref-type="fig"}B; top left blot); this cleavage was unaffected by BSA (negative control; [Figure 6](#fig6){ref-type="fig"}B; bottom blot). Furthermore, the mutant DR4 fragment did not bind LXRα and was cleaved completely, even in the presence of LXRα, indicating that LXRα protects the DR4 element from cleavage ([Figure 6](#fig6){ref-type="fig"}B; top right blot). To further confirm, pull-down assays of nuclear lysates followed by LXRα and CIDEA immunoblots showed that CIDEA^−/−^ T-brites recovered more LXRα than CIDEA^+/+^ T-brites ([Figure 6](#fig6){ref-type="fig"}C) and that this increase was suppressed upon CIDEA re-expression ([Figure 6](#fig6){ref-type="fig"}C; far right lane). These results confirmed that CIDEA binding to LXRα results in its removal from the *UCP1* enhancer releasing LXRα inhibition of *UCP1* transcription. On the other hand, PPARγ recovery was reduced in CIDEA^−/−^ T-brites but recovered upon re-expression of CIDEA ([Figure 6](#fig6){ref-type="fig"}C), suggesting that CIDEA positively regulates PPARγ binding to the UCP1 enhancer.Figure 6CIDEA Directly Binds to LXRα to Derepress UCP1 Transcription during Britening(A) Partial sequence of the WT *UCP1* enhancer containing DR4 (LXRα binding site). T-G (red) point mutation (blue box) flanking DR4 that generated an artificial AatII restriction site. It did not alter LXRα binding to DR4 (data not shown).(B) RFLP-based protein-DNA binding assay showing that LXRα protects synthetic AatII restriction site (lane 4, top left panel). CIDEA increased AatII cleavage efficiency dose dependently (lanes 5--7, top right panel); BSA (negative control) did not stimulate AatII cleavage (lanes 5--7, bottom panel).(C) LXR and CIDEA immunoblots of streptavidin pull-down assays of nuclear fractions that had been incubated with biotinylated dUER~150bp~ containing DR4.(D) CIDEA and LXRα coIP and western blots of total cell (20 kDa cutoff) lysate (input) from CIDEA KO, WT, and WT + T09 LXR ligand T-brites.(E) PLA of CIDEA-LXRα protein-protein interaction in fixed WT T-brites (proteins detected with anti-CIDEA and anti-LXRα antibodies; CIDEA-LXRα interactions within 30--40 nm appear red; blue, Hoechst nuclear counterstain; LDs appear as glossy intracellular globes). Scale bar, 10 μm.(F and G) ChIP-qPCR analysis of LXRα binding to *UCP1* enhancer at −3,919 during Rosi-induced britening of CIDEA^+/+^ (F) or CIDEA^−/−^ (G) adipocytes.(H) Time course ChIP-qPCR analysis of hUCP1 enhancer occupancy at −3,919 by LXRα in developing CIDEA^−/−^ T-brites in which mcom-CIDEA mRNA transfection commenced concomitantly with Rosi induction.(I) Model: Upon induction of human adipocyte britening, increasing concentrations of CIDEA result in CIDEA shuttling to the nucleus, where it interacts directly with LXRα and weakens LXRα binding of the *UCP1* enhancer at DR4, thus increasing transcriptional regulation of UCP1 and thermogenesis.In (F--H), data are mean ± SEM (n = 3). \*\*\*p \< 0.001, and \*\*p \< .01, two-way ANOVAs followed by Bonferroni post-tests.

A previous study reported that CIDEA interacts with liver X receptors in white fat cells ([@bib23]). We studied if there is a direct interaction of CIDEA with LXRα in brite adipocytes. Bidirectional co-immunoprecipitation (coIP) of CIDEA with LXRα ([Figure 6](#fig6){ref-type="fig"}D) suggested a physical interaction between these two proteins. Addition of the LXR ligand increased CIDEA coIP with LXRα, without any effect on LXRα IP ([Figure 6](#fig6){ref-type="fig"}D).

*In vitro* transcription and translation (IVTT)-coupled coIP immunoblot assays confirmed direct interaction of CIDEA with LXRα ([Figure 6](#fig6){ref-type="fig"}D); GFP did not bind either protein. These results showed that CIDEA interacts directly with LXRα. Furthermore, *in situ* proximity ligation assays (PLAs) demonstrated that CIDEA KO abolished the strong association between CIDEA and LXR ([Figure 6](#fig6){ref-type="fig"}E).

Based on the above-mentioned results, we then tested a hypothesis that increased CIDEA in the nucleus during britening of white adipocytes affects LXRα occupancy at the UCP1 enhancer. Indeed, ChIP-qPCR for LXRα showed decreased recovery of *UCP1* enhancer-associated LXRα over the 2 days following induction of britening, in CIDEA^+/+^ ([Figure 6](#fig6){ref-type="fig"}F) but not CIDEA^−/−^ cells ([Figure 6](#fig6){ref-type="fig"}G). Similar results were obtained in the presence of LXR ligand ([Figure S11](#mmc1){ref-type="supplementary-material"}A). CIDEA re-expression reduced LXR association with the *UCP1* enhancer within 24 h in CIDEA^−/−^ cells ([Figure 6](#fig6){ref-type="fig"}H), and this LXRα association with the enhancer recovered as the transient ectopic CIDEA re-expression subsided with time ([Figures 6](#fig6){ref-type="fig"}H and [1](#fig1){ref-type="fig"}D).

Analysis of the *UCP1* promoter-enhancer suggested six additional putative LXR response elements ([Figure S11](#mmc1){ref-type="supplementary-material"}B) ([@bib19]). Functionality testing showed that, other than DR4 at −3,903, none of these were critical for LXRα binding of the *UCP1* promoter-enhancer ([Figure S11](#mmc1){ref-type="supplementary-material"}C).

Since LXRα is known to control a variety of genes in metabolic organs, we next studied if CIDEA-LXRα specifically regulates UCP1.We performed qRT-PCR and ChIP analysis on LXRα-regulated genes in T-brite adipocytes ± CIDEA ([Figure S12](#mmc1){ref-type="supplementary-material"}A). As shown in [Figure S12](#mmc1){ref-type="supplementary-material"}B, except for GLUT4 and APOD none of the LXR-regulated genes showed any significant effect of CIDEA. This observation is in line with a study showing increase in GLUT4 expression in human brown adipocytes along with UCP1 and CIDEA, which makes human brown adipocytes more glucose responsive ([@bib27]).

Discussion {#sec3}
==========

Various studies have shown a positive association of CIDEA expression with healthy metabolic phenotype in humans ([@bib8], [@bib10], [@bib16], [@bib33], [@bib36], [@bib50], [@bib52]). Our present study deciphers a comprehensive cellular and molecular mechanism of CIDEA in the regulation of improved metabolism via regulating thermogenesis and britening by transcriptional regulation of UCP1 in humans ([Figure 6](#fig6){ref-type="fig"}I). Our results show that LXRα is the functional interactor of CIDEA, whereby CIDEA represses its activity on UCP1 enhancer. In this work, we first developed dual-RNA based CRISPR-Cas9 and modified-RNA methodologies to modulate CIDEA expression efficiently in cultured human primary adipocytes derived from hADSCs. The T-brite phenotype was confirmed by heightened thermogenic capacity and expression of brite/beige adipocyte markers ([@bib21]). Importantly, our experiments demonstrated that CIDEA leads to britening of human adipocytes via transcriptional regulation of *UCP1*, wherein CIDEA interacts directly with LXRα, thereby weakening LXRα binding to the *UCP1* enhancer. Our results were supported by a previous study that showed that CIDEA binds to LXRs and regulates their activity in human white adipocytes ([@bib23]). Also, the propensity for UCP1 induction in human adipocytes has been shown to be correlated with CIDEA levels and withdrawal of thermogenic induction led rapidly to instability of CIDEA protein and *UCP1* mRNA *in vivo* ([@bib39]) and *in vitro* (data not shown). Reintroducing CIDEA into CIDEA^−/−^ cells rescued fully functional T-brite formation, as well as a correlation between CIDEA levels and increased UCP1 transcription and activity. This work defines a crucial role of CIDEA in regulating the brite phenotype in human adipocytes.

In rodents, *UCP1* transcription is regulated largely by a combined effect of the CREreach proximal segment and a strong enhancer region \~2.5 kb upstream of the transcription start site; in humans, this region is \~3.9 kb upstream of the transcription start site. Additionally, the human proximal promoter region has more CpG islands than in the mouse (human ENCOD database). Our analysis showed that a 150-bp distal enhancer region (−4,000 to −3,058) of human *UCP1* is DNase 1 hypersensitive, indicating multiple transcription factor-binding sites and suggesting that the mechanisms regulating *UCP1* transcription may differ between humans and mice. In fact, ISO-mediated *UCP1* transcription is weaker in humans than in rodents ([@bib9]). Surprisingly, CIDEA regulation of UCP1 was indirect via a long loop interaction with LXRα. Although CIDEA interacts physically with both LXRα and LXRβ (data not shown), our data indicate that only CIDEA-LXRα interactions are crucial for *UCP1* transcription, perhaps owing to its relatively greater stability. It is possible that CIDEA might remove LXRα from DR4, thereby helping PPARγ to regain control over limiting amounts of RXRα, a heterodimeric partner crucial for LXRα and PPARγ activity.

During adipocyte britening, CIDEA was shuttled to the nucleus via its bipartite NLS, independent of active transport and the classical α/β importin pathway. Notably, we incorporated HA tags into the mutants to keep the CIDEA molecule small enough for passive diffusion ([@bib43]). We hypothesize that specific amino acids in the bipartite NLS may interact with nuclear pore proteins during passive diffusion to overcome a steep concentration gradient. These nuclear pore proteins may influence the passive diffusion rate.

CIDEA knockout mice were reported to have a lean phenotype and resistance to diet-induced obesity. It was explained on the basis of reduced UCP1 activity by CIDEA by physically interacting with it in mitochondria ([@bib51]), although later studies showed that CIDEA is not localized in adipocyte mitochondria ([@bib7], [@bib36], [@bib48]). These seemingly disparate results in CIDEA function might also be due to increased lipolysis in whole-body CIDEA-knockout mouse, which produces excessive intracellular FFAs that might cause increased respiration through non-specific protonophoric FFA actions and PTP opening ([@bib28]) resulting in increased thermogenicity. A recent study showed that, in adipose-specific CIDEA transgenic mouse, CIDEA adipose expression is proportional to tissue briteness and UCP1 expression was increased owing to adipocyte hyper-recruitment from a mixed adipose tissue ([@bib11]). Given our observation that robust UCP1 expression precedes brite-adipocyte specific gene expression during britening, we hypothesize that CIDEA-mediated de-repression of UCP1 could create mitochondrion-derived retrograde signaling to the nucleus for complete transdifferentiation of adipocytes into T-brites. It is also possible that inhibition of LXRα suppression by CIDEA could affect a broader network of genes, beyond *UCP1*, that drive adipocyte britening. For example, our observation of reduced DIO2 (type II iodothyronine deiodinase) expression in CIDEA^−/−^ adipocytes may be relevant for thermogenesis and britening given that thyroid hormones have been linked with brown adipocyte formation and thermogenesis in mice via DIO2 upregulation ([@bib49]).

During thermogenic stimulation by PPARγ or cAMP ([@bib6]), LXRα is recruited to the *UCP1* enhancer ([@bib47]). Our study showed that both of these conditions augmented CIDEA expression and CIDEA enrichment in the nucleus. It is notable that *UCP1* transcription was decreased by nearly half but not completely abolished in our CIDEA^−/−^ cells. Potential explanations for this remaining *UCP1* transcription include initial dismissal of LXRα by PPARγ enabling basal *UCP1* transcription, CRE downstream of the PPAR response element activating *UCP1* transcription, and/or Rosi initiating a PPARγ-independent B38/mitogen-activated protein kinase phosphorylation cascade. Our time course ChIP analysis indicated that CIDEA was involved in the maintenance and robustness of *UCP1* transcription, rather than its initiation, during adipocyte britening.

CIDEA does not influence the chromatin retention of LXRα but rather interacts with it to alter its localized repressor activity on *UCP1*. Since CIDEA is a multifunctional protein, we performed a comprehensive transcriptome analysis in britened human white adipocytes ± CIDEA. As shown in [Figure 3](#fig3){ref-type="fig"}, UCP1 was the most upregulated gene in T-brite adipocytes. In conclusion, this study established a previously unidentified role of CIDEA in the transcriptional regulation of thermogenesis in human adipocytes and their britening.

Limitations of the Study {#sec3.1}
------------------------

Our study defines the molecular role of CIDEA as a regulator of thermogenesis in human adipocytes. We have shown that CIDEA directly binds to LXRα and repress its activity on UCP1 enhancer. Although this study identified the role of CIDEA as a regulator of thermogenesis in human primary adipocytes, its *in vivo* role in humans remains to be proven. Presently, our results demonstrate that, during britening of human adipocytes, CIDEA expression is increased resulting in translocation to the nucleus via a bipartite NLS. Future studies are required to identify the NLS-binding molecules that may facilitate the entry of CIDEA into the nucleus.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#appsec1}
==========================

The mRNA template sequences and their Gene Bank accession number is provided in the [Data S1](#mmc2){ref-type="supplementary-material"} dataset file.
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